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Abstract 
 
 
As bacterial infectious diseases are a major cause of morbity and mortality throughout 
the world, and many causative organisms are resistant to currently available antibiotics, 
the motivation for the development of new drugs is readily apparent.  A number of 
natural products exhibiting antimicrobial activity possess a tetramic acid (2,4-
pyrrolidinedione) functional group.  As their antibacterial mechanism of action is 
different from that of many of the currently available antibiotics, these compounds have 
potential to serve as a basis for a pharmacophore in synthetic compounds.  However, 
toxicity to eukaryotic cells is frequently a problem with currently known tetramic acids.  
The purpose of the project, as outlined in the following pages, is to demonstrate a method 
of synthesis of a small library of compounds containing the tetramic acid ring, and to 
illustrate their structure-activity relationship as agents both having activity against Gram-
positive bacteria and possessing low hemolytic activity.  Chapter One takes an overview 
of a number of the different classes of antibiotics available today, with emphasis on their 
method of action, then covers several naturally occurring tetramic acid compounds with 
antibiotic activity, and finally methods of synthesis.  Chapter Two details the methods 
used to synthesize and characterize the set of compounds and examines their activity 
against a set of Gram-positive bacteria, with the purpose of clarifying their structure-
activity relationship.   
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Chapter 1.  Introduction 
 
 
There is an urgent need for antibacterial agents with distinct modes of action due to 
increased prevalence of bacteria resistant to current clinically used antibiotics.  The need 
for novel antibiotics is well demonstrated by the emergence of strains of multiple-drug 
resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA). S. aureus 
is a frequent cause of life-threatening diseases, such as pneumonia, endocarditis, and a 
condition known as necrotizing fasciitis, an infection of the fascia that can spread quickly 
throughout the body and frequently necessitate amputations of affected limbs.  These 
bacteria are also the most common cause of infections of the skin, such as scalded skin 
syndrome and impetigo, which can worsen and lead to infections of deeper tissue, such as 
cellulitis or erysipelas.  These bacteria are normally commensal residents of skin, but can 
cause infection upon entering breaks (typically open wounds, although hair follicles can 
sometimes be a route of entry.)  In addition, these bacteria are sometimes a cause of 
infectious keratitis (inflammation of the cornea), which can lead to scarring and loss of 
eyesight.  In the clinic, topical antibiotics, when used as prophylactics, can prevent 
serious S. aureus infection in high-risk post-surgical patients, and are useful as treatments 
for some types of skin infections such as impetigo. 
 
Since its emergence in the 1960s, MRSA has primarily been a major cause of hospital-
acquired infection.  In recent decades, however, community-acquired MRSA (CA-
MRSA) strains have emerged and are now a significant cause of skin and soft tissue 
infections in several community settings across the United States.  These strains are 
different from hospital-acquired strains, which tend to be less virulent, and they are 
increasingly prevalent in both community and hospital settings.  In view of the etiology 
of disease by CA-MRSA and the growing concern stemming in both community and 
hospital settings, the need for strategies to counteract this organism is even more 
pressing. 
 
Recently, the synthesis of a series of novel tetramic acid (2,4-pyrrolidinedione) 
compounds that possess effective antibacterial activity has been reported.1, 2  Although 
these agents are effective in vitro, they exhibit toxicity to mammalian cells, with a 
pronounced tendency toward lysis of red blood cells.1, 2  This attribute would be expected 
to cause undesirable or harmful side effects, ranging from skin irritation to systemic 
toxicity, if the tetramic acids were used clinically.  These agents possess lipophilic 
functional groups, which are thought to be the root of the hemolytic activity due to 
eukaryotic cell membrane penetration and disruption.  The consequent focus of this 
synthetic project is to improve the safety profile of this class of drugs by introducing 
functional groups with reduced lipophilicity, with the aim of minimizing their hemolytic 
activity but retaining their antimicrobial activity.  Furthermore, a reduction in the 
cytotoxicity of tetramic acids could lead to novel molecules with greater potential for 
systemic administration.  This chapter will begin by examining the properties and 
mechanisms of action of current clinical antibiotics used to treat skin and skin structure 
infections, then cover the mode of action of known tetramic acid antibiotics and, finally, 
methods for their synthesis. 
1 
Current Antibiotics Used to Treat Skin and Soft Tissue Infections 
 
As shown in Table 1.1, a number of antibiotics are currently used for the treatment of 
skin and soft tissue infections; their methods of action (MOAs), however, are different 
from those of tetramic acids.  This section will cover a sample of the variety of 
compounds currently in clinical use for such infections. 
 
 
Inhibitors of Bacterial Cell Wall Synthesis 
 
Penicillins 
 
The development of β-lactam antibiotics was initiated in 1928 when Fleming noted the 
antimicrobial properties of the a substance produced by spores of Penicillium  
chrysogenum mold contaminating a culture of Staphylococcus aureus.3  Isolation of the 
active component, Penicillin F (Figure 1.1), was accomplished in the 1940 by Florey, 
Chain, and Heatley, and its clinical efficacy demonstrated shortly thereafter.  Penicillin F 
did not experience widespread clinical use, but a number of variations on it were soon 
isolated, and some of these alternative penicillins are still in use today, most notably 
benzylpenicillin, also termed penicillin G (Figure 1.1).  Subsequent work on this 
molecule permitted numerous semi-synthetic analogues with improved antimicrobial 
spectrum and durability against bacterial defenses to be produced.  The activity of the β-
lactam antibiotics lies in prevention of bacterial cell wall biosynthesis.  The cell wall of 
both Gram-positive and Gram-negative bacteria contains a cross-linked peptidoglycan 
layer that provides support against lysis of the cells’ contents via osmosis.  The 
peptidoglycan layer consists of chains of alternating glucose and N- acetylmuramic acid 
connected by O-glycosidic bonds.  These chains are cross-linked via amino acids 
connected to the muramic acid subunits to provide greater strength; typically, in S. 
aureus, five amino acids are connected to the muramic acid, and to these amino acids are  
 
 
Table 1.1.  Methods of Action of Existing Topical Antibiotics. 
 
Drug Type Point and Method of Action 
Penicillins Cell wall assembly (inhibition of peptidoglycan cross-linking) 
Cephalosporins Cell wall assembly (inhibition of peptidoglycan cross-linking) 
Bacitracin Cell wall assembly (inhibition of dephosphorylation) 
Mupirocin Protein synthesis (inhibition of isoleucyl t-RNA aminoacylation) 
Fusidic acid Protein synthesis (inhibition of elongation factor G) 
Tetracyclines Protein synthesis (inhibition of tRNA binding to ribosomal site) 
Silver sulfadiazine DNA synthesis (inhibition of folate biosynthesis) 
Daptomycin Cell membrane permeabilization (induction of K+ ion efflux) 
 
Source:  Modified with permission from Gelmetti, C. Local antibiotics in dermatology.  
Dermatologic Therapy, 2008, 21, 187-195.4 
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Figure 1.1.  Earliest Penicillins. 
 
 
attached a pentaglycine chain that connects the amino acids between peptidoglycan 
chains.  In the cross-linking, or transpeptidation step, a preassembled, peptidoglycan 
chain (losing an alanine in the process) is attacked by a terminal glycine to connect the 
chains.  This process is catalyzed by the enzyme transpeptidase.  The β-lactams prevent 
cell wall cross-linking by mimicking the D-Ala-D-Ala substituent present in the cross-
linking step; consequently, the β-lactam is attacked by a penicillin-binding-protein’s Ser-
OH, leading to an irreversible attachment of the penicillin molecule to the protein.  With 
the penicillin-binding proteins rendered inactive, peptidoglycan cross-linking cannot 
occur, and so bacterial cell walls weaken, leading to eventual lysis and cell death. 
 
The earliest penicillins’ C7-N1 amide bond was highly acid labile, necessitating 
parenteral administration to avoid the strongly acidic environment of the stomach; 
however, α-amino substitution to the amide with electron-withdrawing groups, as in 
ampicillin (Figure 1.2) helped to overcome this limitation.  A major impediment to the 
efficacy of the first β-lactams was the bacterial development of β-lactamases, enzymes 
that hydrolyze the amide bond of the lactam ring, rendering it ineffective.  Semi-synthetic 
analogues of penicillin with resistance to lactamase-induced cleavage have been 
developed; a key component of the structure-activity relationship (SAR) of these resistant 
penicillins is the substitution of bulky groups at the α-amino position (as in methicillin, 
Figure 1.2) to inhibit the action of β-lactamases without significantly reducing affinity for 
penicillin-binding proteins. 
 
 
Cephalosporins 
 
Cephalosporins (Figure 1.3) are structurally and functionally highly similar to penicillins, 
the main difference being an eight-membered rather than seven-membered bicyclic main 
ring, which confers greater stability and consequent lower reactivity.  This reduced 
reactivity is typically compensated for by the presence of a leaving group (R) at the ring 
carbon β to the carboxyl (COOR) group.  Many cephalosporins have been generated 
because of their inherent resistance to β-lactamases and increased spectrum of activity. 
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Figure 1.2.  Modified Penicillins. 
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Figure 1.3.  General Structure of Cephalosporins. 
4 
Peptide-Based Cell Wall Inhibitors 
 
An inhibitor of cell wall biosynthesis commonly in use as an antibacterial ointment is 
bacitracin, a mixture of cyclic peptides synthesized by strains of Bacillus licheniformis.5,6  
The main component of the mixture is a cyclic oligopeptide designated Bacitracin A 
(Figure 1.4).  Bacitracin functions by inhibiting the dephosphorylation of the C55-
isoprenyl pyrophosphate, which, in its dephosphorylated state, carries assembled 
peptidoglycan units (with their attached amino acids) to an endogenous acceptor outside 
the cell membrane.5,6  With the dephosphorylation step inhibited, the cell wall cannot be 
assembled.  Bacitracin is systemically toxic in humans, however, and thus is limited to 
topical application. 
 
 
Protein Biosynthesis Inhibitors 
 
Several classes of topical antibiotics prevent the synthesis of proteins via action on 
ribosomal components.  These include mupirocin, fusidic acid, and tetracyclines. 
 
 
Mupirocin 
 
Mupirocin (Figure 1.5), a mixture of bacterially synthesized fatty acids, is employed in 
the treatment of skin infections caused by S. aureus.  Mupirocin is used solely as a topical 
antibiotic since it undergoes in vivo hydrolysis, which prevents it from being effective 
systemically.  It functions by inhibiting bacterial isoleucyl t-RNA synthetase.  When this 
enzyme is blocked, isoleucine cannot be connected to a molecule of t-RNA.  At low 
concentrations, mupirocin is bacteriostatic, as its starvation of the cellular supply of 
isoleucine arrests protein synthesis and triggers repression of RNA synthesis.7  At higher 
concentrations, the mixture is bactericidal due to its blockade of protein synthesis and 
multiple other effects on the cell, including cell wall damage. 
 
 
Fusidic Acid 
 
A compound isolated from the fungus Fusidium coccineum,4 fusidic acid (Figure 1.6) 
inhibits protein biosynthesis by forming a complex with elongation factor G (EF-G) that 
prevents it from dissociating from the ribosome.8  EF-G catalyzes the transfer of tRNA 
from the ribosomal A site (to which an aminoacylated tRNA binds during protein 
synthesis) to the P site (where the growing peptide chain is located prior to linkage with 
the A site amino acid), but must dissociate from the ribosome to leave space for the next 
aminoacylated tRNA to enter the A site.  Halting this cycle does not kill bacteria, but 
does halt their reproduction; fusidic acid’s action is specific to prokaryotic ribosomes.  Its 
main disadvantage is rapid emergence of resistance compared with other types of 
antibiotics; it is also effective solely against Gram-positive bacteria.   
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Figure 1.4.  Bacitracin. 
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Figure 1.6.  Fusidic Acid. 
6 
Tetracyclines 
 
Tetracyclines (Figure 1.7) are a semi-synthetic class of drugs often prescribed as a 
treatment for acne vulgaris.  Their mode of action is binding to the bacterial 30S 
ribosomal subunit and inhibition of aminoacyl-tRNA binding to the A site.  Tetracyclines 
are clinically bacteriostatic, in part because their interaction with the ribosome is 
reversible.9  Microbial resistance to the tetracycline class, which occurs via efflux pumps, 
ribosomal protection proteins (which interact with the ribosome and render it immune to 
tetracycline-induced inactivation), and enzymatic inactivation of the drug, is now 
widespread.9  This situation has significantly reduced their clinical utility.   
 
 
DNA Biosynthesis Inhibitors 
 
The first class of antimicrobials was a variety of fully synthetic drugs known as the 
sulfonamides.  This class of drugs acts by halting the biosynthesis of tetrahydrofolate, an 
essential factor in the synthesis of the DNA bases guanine and adenine.  Specifically, 
they compete with the natural substrate (para-aminobenzoic acid) for the active site of 
dihydropteroate synthase.  Sulfonamides act selectively because bacteria synthesize 
tetrahydrofolate de novo, whereas humans synthesize it from dietary folic acid.  This 
inhibition of DNA synthesis does not destroy bacteria, but prevents reproduction, 
allowing the host’s immune system to eliminate the infection.  As such, sulfonamides are 
classified as bacteriostatic (i.e. inhibitors of bacterial reproduction) rather than 
bactericidal.  The most relevant preparation, commonly used to treat burns, is silver 
sulfadiazine salt (Figure 1.8). 
 
 
Membrane-Destabilizing Agents 
 
Daptomycin (Figure 1.9), a cyclic lipopeptide derived from Streptomyces roseosporus, 
possesses an unusual antibacterial mode of action in that it depolarizes bacterial 
membranes by causing the Ca2+-dependent gradual release of K+ ions, but without 
forming pores.10  This activity severely and quickly reduces the viability of a bacterial 
culture to nearly zero, presumably because the depolarization of the membrane causes 
rapid release of necessary intracellular ions.10  The development of this molecule is 
significant, as it demonstrates a novel mode of action on the bacterial membrane.  As it  
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Figure 1.7.  General Structure of Tetracyclines. 
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Figure 1.8.  Silver Sulfadiazine. 
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Figure 1.9.  Daptomycin. 
8 
selectively permeabilizes bacterial as opposed to mammalian membranes, it provides a 
precedent for the pursuit and development of tetramic acids—which act in a similar 
fashion—as clinically relevant drugs.   
 
 
Naturally-Occurring Tetramic Acids 
 
Tetramic acids, or pyrrolidine-2,4-diones, are an important class of naturally occurring 
molecules synthesized by numerous organisms.  Members of this naturally occurring 
class exhibit various significant biological activities, including antimicrobial activity.  A 
number of methods for their synthesis are present in the available literature. The pursuit 
of compounds containing tetramic acid groups with therapeutic properties has been 
undertaken for several decades, although comparatively few studies have been devoted 
toward their potential as anti-infective agents. 
 
A number of tetramic-acid containing molecules with demonstrated antimicrobial activity 
have been isolated from a variety of natural sources.  However, the types of substituents 
on the common pyrrolidine ring (Figure 1.10) vary widely, as might be expected.  
Wangun and Hertweck11 have reported the isolation of a small set of fungal isolates with 
5-tyrosyl and 3-(dimethylnonyl)acetyl substitution; activity against Mycobacterium 
vaccae was observed.  Equisetin (Figure 1.11), first isolated by Burmeister et al.,12 was 
first shown to be effective against several species of gram-positive bacteria, but not 
against the majority of tested Gram-negative bacteria.  The compound trichosetin (Figure 
1.11), isolated by Marfori et al.,13 is an N-desmethyl homolog of equisetin containing a 5-
(ethanol) and 3-[1,6-dimethyl-2-propenyl 1,2,4-α,5,6,7,8,8-α octahydronaphthyl acyl] 
substituent and, notably, having activity against S. aureus and Bacillus subtilis at 
nanogram concentrations.  The actinomycete derivatives Bu-2313A and B (Figure 1.11) 
have demonstrable activity against the common skin pathogens Streptococcus pyogenes 
(S. pyogenes) and Propionibacterium acnes,14 particularly the former.   
 
Streptolydigin (Figure 1.11), a bacterial isolate, has been shown to inhibit RNA 
polymerase in a fashion similar to the rifamycin compounds currently in clinical use;15  as 
a consequence, it indirectly inhibits protein biosynthesis.  Examination of its method of 
action has revealed that although it acts faster at inhibiting RNA polymerization and 
pyrophosphate exchange with ribonucleotide triphospates, both its pyrophosphate 
exchange sensitivity and inhibitory capacity are weaker by a factor of approximately one 
hundred.15  The structurally similar compound tirandamycin16 (Figure 1.11) also inhibits 
Escherichia coli-derived RNA polymerase, but is not selective in that it also inhibits 
mammalian RNA polymerase16 and mammalian mitochondrial respiration.17  Both 
compounds demonstrate activity against several Gram-positive but not Gram-negative 
bacteria, with bacteria of the Bacteroides genus being the only Gram-negative 
exception.18 
 
The melophlins, a sizable group of 3-acyl tetramic acids, (Figure 1.11), are (chiefly) 
derived from the marine sponge Melophlus sarassinorum; at least nineteen such 
compounds have been isolated.19-21  Their structures are similar in that they are all N- 
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Figure 1.10.  Tetramic Acid Ring Structure. 
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Figure 1.11.  Naturally Occurring Antimicrobial Tetramic Acids. 
10 
methylated, and possess either an H or CH3 substitution at the C-5 position; their key 
differences are the length of the main alkyl chain (C12 to C16, including carbonyl) of the 
3-acyl substituent and the position of the chain’s branching.  Some of the melophlins 
have biological properties, including cytotoxic (translating to potential anticancer drugs) 
and antibacterial activity; the latter category includes melophlins C and G, which both 
have demonstrable activity against Bacillus subtilis and S. aureus.22 
 
A potential biological function of compounds with the tetramic acid moiety was proposed 
by Kaufmann et al.,23 in which an autoinducer N-acylhomoserine lactone produced by the 
Gram-negative bacterium Pseudomonas aeruginosa unexpectedly underwent aqueous 
solvent-promoted rearrangement to a tetramic acid moiety.  Both the precursor molecule  
and the tetramic acid product (Figure 1.11) exhibited inhibitory activity against nine 
different species of Gram-positive bacteria, including several strains of the Gram-positive 
bacterium Bacillus cereus.  However, no notable activity against Gram-negative species 
E.  coli or Salmonella typhimurium was observed.  It was proposed that the MOA of this 
product is similar to that of reutericyclin (see below); namely, it functions as an 
ionophore and dissipates the bacterial transmembrane difference of pH, leading to cell 
lysis.23,24  It also exhibits a high inhibitory constant due to ready penetration of the cell 
membrane via its high lipophilicity.23,24 
 
It should be noted that that these natural products were, albeit with exceptions, found to 
be considerably more active against Gram-positive bacteria than Gram-negative bacteria.  
The most likely explanation is that tetramic acid compounds are unlikely to penetrate 
fully the outer lipopolysaccharide layer of Gram-negative bacteria in order to reach the 
bacterial inner membrane. 
 
 
Tetramic Acid Structure-Activity Relationship Investigations 
 
Numerous syntheses of products containing tetramic acid moieties have been undertaken, 
several of which have been directed toward the synthesis of natural products; these 
syntheses may have a use in initiating optimization of the structure-activity relationships 
exhibited by natural products.  Tetramic acids not found in nature also comprise a portion 
of syntheses undertaken thus far, although comparatively few studies have focused on the 
SAR of substitutions.  A number of natural products, including those mentioned above, 
possess a diene chain connected to the 3-acyl group.  A study by Rosen et al.25 
investigated the effects of varying terminal aromatic groups on this 3-dienoyl substituent 
in an effort to mimic the RNA polymerase inhibitory activity of streptolydigin and 
tirandamycin A; these synthesized compounds either lacked C-5 or N-1 substitution or 
were methylated at these positions.  The noted SAR was that N-methylation provided 
only a minor reduction in minimum inhibitory concentration, whereas C-5 methylation 
dramatically weakened activity.  An acyclic terminal functional group had far weaker 
activity than an aromatic ring, as well.  Toda et al.14 tested the effects of substitution at 
the tetramic acid’s C-5 position on the aforementioned Bu2313-A and B, and found that 
functionalities that were electron-withdrawing or larger than ethyl tended to have reduced 
11 
activity against Propionibacterium acnes and Streptococcus pyogenes, particularly the 
latter. 
 
Attention should be drawn to the fact that the active compounds noted above lack 
extensive substitution on the N-1 position; rather, all of them possess an N-H or N-CH3 
functionality.  They also typically possess 3-acyl substitution, frequently with either 
unsaturated alkyl chains or a double bond at the carbon β to the carbonyl carbon.  This 
fact leaves the question open as to the potential, if any, of variations on substitutions at 
the N-1 position.  Yendapally et al.1  tested the effectiveness of 3-acyl tetramic acids 
without substitution on the 3-acetyl functional group, and with varied N- and 5-
substitutions.  A trend found in the activity of this series of compounds was that 
lipophilic functional groups (long alkyl chains or aromatic and cyclic hydrocarbons) at 
the N-position conferred the greatest antibacterial activity, although the leucine, 
isoleucine, valine, and phenylalanine-based lipophilic side chains at the 5-position 
conferred few differences in potency relative to each other.1   
 
 
Synthetic Methods for Tetramic Acids 
 
Biosynthesis of tetramic acids is most often stereospecific, with the following general 
assembly procedure:  The N-1, C-5, and C-4 positions on the ring are most commonly 
derived from an amino acid (with the 5-position substituted with the amino acid side 
chain), while the C-2 and C-3 positions are provided from acetate, which, in the case of 
3-polyenoyl tetramic acids, is connected to preformed polyketides.26 
 
Assembly of the 2,4-pyrrolidine diketone ring itself and introduction of varied 
substituents at the 1-, 3-, and 5-positions are the main challenges faced in synthesis of   
analogues.  Toward this end, a number of synthetic methods have been devised.  
Although numerous methods of introducing 3-substituents are available, a great many 
bioactive tetramic acids possess 3-acyl functional groups, and it is these that are most 
relevant to the current project.  As such, the following discussion of synthetic methods 
will be limited to those that produce the 3-acyl ring component. 
 
The most common method of synthesis of the 3-acyl substituted ring is a version of the 
Dieckmann condensation (Figure 1.12), involving base-promoted intramolecular C-
acylation of N-acetoacetyl α-amino esters.27  (Competitive reactions involving other 
acidic protons in the molecule would not be expected due to steric hindrance.)  This 
condensation typically takes place in protic solvent with a strong base, such as sodium 
methoxide or potassium tert-butoxide (Scheme W; Figure 1.13).28  The chief problem 
with this method, however, is that racemization at C-5 is common, as the C-5 hydrogens 
are acidic (a condition stemming from their proximity to the electron-withdrawing 
heteroatom and C-4 carbonyl) and can be readily removed under the strongly basic 
conditions needed for the condensation.  A few methods exist for generation of the 
acetoacetyl α-amino esters, including—if the desired final tetramic acid is to be 
unsubstituted at C-5—condensation of an alkylaminoacetonitrile with diketene; the 
molecule can be converted to a lithium enolate and cyclized (Scheme X; Figure 1.13).29   
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Figure 1.12.  Lacey-Dieckmann Condensation Mechanism. 
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Figure 1.13.  Synthetic Pathways to 3-Acyl Tetramic Acids. 
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The N-acetoacetyl ester intermediates can also be generated by reaction of α-amino esters 
with a diethylphosphonate acetone diketene adduct, followed by Dieckmann  
condensation (Scheme Y; Figure 1.13).  An advantage of this method is that it allows  
Wadsworth-Emmons olefination to be performed subsequent to ring formation, if the 
final molecule is to be a 3-dienoyl compound.30  A reported synthesis using an 
acetoacetyl ester attached to a solid support noted near-quantitative yield, but made no 
mention of stereoselectivity.31  Alternative protocols for ring formation require 
subsequent 3-acylation.  One such method, employed by Jouin et al.,32 employs 
Knoevenagel condensation of α-amino acids with Meldrum’s acid, followed by heating to 
cause intramolecular amidation with elimination of acetone and carbon dioxide.  Lewis 
acids, such as boron trifluoride or titanium tetrachloride, can couple acyl chlorides to the 
ring.   
 
An additional method of stereospecific ring formation uses a domino reaction sequence 
wherein (triphenylphosporanylidene)ketene (Ph3P=C=C=O) is added across the terminal 
amine of a chosen amino acid precursor to form active agents that rapidly undergo intra- 
Wittig reaction to form the tetramic acid ring (Scheme Z; Figure 1.13) .26,33  This method 
is largely free of C-5 epimerization and can be performed under pH-neutral conditions. 
The pathway toward ring formation without inclusion of the 3-acyl substituted tetramic 
acids involves synthesis of the core ring, followed by 3-acylation.  The known methods 
for acylation, however, each suffer limitations on applicability in the presence of various 
functional groups.26  The 4-O acylation of the ring with the desired carboxylic acid, 
followed by a shift to the C-3 position, is accomplished by addition of the carboxylic acid 
along with dicyclohexylcarbodiimide (DCC) and 4,4-dimethylaminopyridine (DMAP), as 
initially reported by Hori et al.34  Reaction of the completed N-methyl, 3-unsubstituted 
tetramic acid ring with thallous ethoxide, followed by acetyl fluoride, was reported to 
yield 3-acetyl product; however, analogous reaction with acyl fluorides with longer 
chains tended to give 4-O-acylated product instead.29 
 
 
Reutericyclin Properties and Synthetic Approaches 
 
Reutericyclin (Figure 1.14) is a natural product of significant interest, as it exhibits 
antimicrobial activity in a fashion somewhat different from known antibiotics.  The 
compound, isolated from Lactobacillus reuteri, is found in sourdough bacterial colonies, 
and has demonstrable bactericidal activity against other microbial residents.  In a fashion 
similar to organic acids used in food preservation,24 reutericyclin acts as a proton 
ionophore and selectively dissipates bacterial cell membrane ΔpH, leading to reduced 
chemopotential energy (necessary for ATP biosynthesis and active transport of 
molecules) and eventual cell death.  (The pKa of reutericyclin is in the range of 2 to 3.24)  
It is active against Gram-positive bacteria, but not Gram-negative species; the production 
of reutericyclin is thought to give the bacterium a competitive advantage against rival 
species.35  The molecule’s amphiphilic nature is thought to allow it to penetrate the cell 
lipid layer while acting as a depolarizing agent via its tetramic acid ring.  As L. reuteri is 
a frequent resident of human and animal intestinal microflora, as well as food  
preparations,36 it represents a possible lead compound for safe antimicrobial agents. 
15 
NO
O
OH
O6  
 
 
Figure 1.14.  Reutericyclin. 
 
 
Several synthetic routes to reutericyclin have been devised, with varying degrees of 
success; these routes have been mentioned above and are outlined in Figure 1.15.  The 
first synthesis, as noted by Böhme et al,37 employed the aforementioned method of 
cyclization of N-acylated amino acid with Knoevenagel condensation with Meldrum’s 
acid, followed by heat-promoted cyclization32 and 3-acylation catalyzed by titanium 
tetrachloride; the final step caused racemization at the C-5 position (Scheme X, Figure 
1.15).  A more successful synthetic route employed N-acetoacetylation with N-
(hydroxysuccinimidyl)acetoacetate followed by Dieckmann condensation with sodium 
ethoxide, then N-acylation promoted by butyllithium; the final compound was produced 
in 80% enantiomeric excess (ee) (Scheme Y, Figure 1.15).37  The most effective chiral 
synthesis employed the domino Wittig sequence described above,26 employing D-
isoleucine benzyl ester and Ph3=C=C=O to cyclize the ring, followed by boron 
trifluoride-promoted acylation and ultimate N-deprotonation/acylation, to produce 
reutericyclin in 95% ee (Scheme Z, Figure 1.15).26 
 
Having explored the mechanism of action of currently available antimicrobial agents and 
surveyed the potential of existing tetramic acids, I will, in the next chapter, detail how 
knowledge of the structure-activity relationship of tetramic acids, and methods for 
synthesizing them, may be used to achieve the goal of developing active compounds with 
an improved safety profile. 
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Figure 1.15.  Synthetic Routes to Reutericyclin. 
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Chapter 2.  Synthesis, Characterization, and Evaluation of Substituted Tetramic 
Acid Compounds as Antibacterial Agents 
 
 
Introduction 
 
The current series of compounds was based on a previously synthesized series of 
antibacterial tetramic acids by Yendapally et al.1,2 in which a set of 3-acetyl tetramic acids 
resembling the natural antibiotic reutericyclin was made.  These compounds possessed 
varying amino acid-derived 5-substitutions (phenylalanine, leucine, isoleucine, and 
valine).  Several N-substituents, which were more stable to enzymatic degradation than 
the N-acyl substituent of reutericyclin, were incorporated into these compounds as well.  
The tested compounds with the most potent antibacterial activity were, in general, those 
with highly lipophilic N-substituents; these substituents were theorized to be effective at 
penetrating bacterial cell membranes.  Although these compounds exhibited potent 
antibacterial activity in vitro, concerns arose about their cytotoxicity, particularly a 
hemolytic effect on human red blood cells, which was thought to stem from a 
combination of the membrane-penetrating capacity imparted by the highly lipophilic N1- 
and C5-substituents and the acidic nature of the tetramic acid ring.2  In light of these facts, 
in this study, different 5-substituents generated from polar and basic amino acids were 
employed in an effort to balance the negative charge of the acidic tetramic acid ring and 
confer greater amphiphilicity, thus altering interaction with mammalian membranes.  The 
working hypothesis is that reduction of eukaryotic membrane damage could reduce 
clinical side effects such as skin irritation (if used topically) or hemolytic anemia (if 
administered intravenously).  It is worth noting that many non-lytic membrane-active 
antibiotics are amphiphilic, perhaps most notably daptomycin.  A novel series of 5-
substituted tetramic acids was synthesized, and the compounds were tested for their 
antimicrobial efficacy and hemolytic activity.   
 
 
Results and Discussion 
 
 
Synthetic Evaluation 
 
The synthetic route utilized for this project (Figure 2.1), adapted from the protocol of 
Yendapally,2 was chosen because of its established effectiveness in synthesizing 3-acyl 
tetramic acids with nonpolar functional groups at the ring’s N and C-5 positions.1,2  
Based on the antimicrobial activity of these prior compounds, the N-substituted 
functional groups expected to confer the strongest activity were 4-phenylbenzyl (a), 
myrtenyl (b), and decyl (c). 4-Ethylbenzyl (d) and 4-methoxybenzyl (e) (Figure 2.1) were 
also used to test the effect of varying the para-substituent on the benzyl group, relative to 
4-phenylbenzyl.  After completion of the synthesis of these compounds, preliminary 
antimicrobial and hemolytic studies were performed.  Based on these findings, the 
myrtenyl group, which resulted in minimal hemolysis compared with activity against  
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Figure 2.1.  Synthesis of Tetramic Acids and Derivatives.  Reagents and conditions: 
(a) (i) THF, Et3N, MgSO4, 5 h, rt (ii) MeOH, NaBH4, 30 min, rt (b) CH2Cl2, Et3N, 6 h, 
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S. aureus, was selected to be paired with the tyrosine side chain as a different polar N-
substituent to produce compound 6 (Figure 2.1), via the same synthetic scheme.  In the 
initial synthetic step for all the compounds, amino acid (tyrosine or N-Boc lysine) methyl 
ester hydrochloride was N-substituted by reductive amination with aldehydes 1a-e and 
Et3N as basic catalyst in anhydrous THF, using anhydrous MgSO4 to maintain anhydrous 
conditions.  The resulting imine intermediates were reduced with NaBH4 in methanol to 
form secondary amines, in total yields between 29.6-82.9%.  The secondary amine 
products 2a-f were acylated with diketene in CH2Cl2 at reflux, employing Et3N in 
catalytic amount, to form N-acetoacetyl-α-amino esters in yields between 36.2-79.0%.  
To form the tetramic acid rings, the N-acetoacetyl- α-amino esters 3a-f were cyclized via 
Lacey-Dieckman condensation27 with sodium or potassium t-butoxide in t-butanol (these 
bases were chosen for their reduced tendency to cause isomerization)28 to give nearly 
quantitative yields.  The rather high observed yields for these compounds probably derive 
from the presence of a remnant of the reactant, as the reaction mixtures were subjected to 
aqueous/organic extraction but not chromatography.  These tetramic acids 4a-f were 
tested for antimicrobial activity.  For further testing, the Boc group was, as per the 
procedure of Rakesh et al.,38 removed from the N-Boc lysine-derived tetramic acids with 
TFA in THF to form primary amines 5a-e as their TFA salts.  The TFA cleavage step 
proved to be the most difficult, with incomplete reaction being the norm and frequently 
requiring a second run of the reaction before MS testing demonstrated the disappearance 
of the starting material. 
 
The main divergence of structure, compared with the prior series, was the functional 
group at the C-5 position.  Greater difficulty was expected in the use of polar amino acid 
starting materials, as they had potential to interfere with each of the three main steps (N-
alkylation, N-acylation, and ring closure), and to make purification difficult, as highly 
polar functional groups tend to adsorb strongly onto silica-based chromatography 
columns.  These difficulties were circumvented by the use of N-Boc-protected lysine; 
however, cleavage of the protecting group with trifluoroacetic acid proved difficult, 
necessitating comparatively long reaction times and repeated evaporation to remove the 
material, and forming salts rather than the desirable free base.  The final products, 
whether protected or deprotected, were also highly polar and resistant to elution on thin-
layer silica plates, and so silica-based flash chromatographic purification was not 
attempted. An inherent difficulty in assigning NMR peaks to the products was also 
encountered due to the presence of tautomers in the N-acylacetoamine intermediates 3a-e 
(Figure 2.1) and in the ultimate tetramic acid products.  There are a total of nine possible 
tautomers of 3-acyl tetramic acids,39 but only four, shown in Figure 2.2, are present in 
detectable concentrations.  They consist of internal and external pairs which interconvert 
too rapidly to be detected on the NMR time scale, although the rate of conversion 
between internal and external pairs is sufficient to determine their ratio of concentration 
if their NMR signals are distinguishable.39  Intramolecular hydrogen bonding, as shown 
in Figure 2.2, would be expected to improve the stability of the enol tautomers A and C 
of the 3-acyl group.  For these reasons, mass spectrometry was the most useful technique 
to determine the presence or absence of the final product.  A similar use was made of 
reversed-phase HPLC, which was invaluable in determining the purity of the ultimate 
reaction mixtures, as the tetramic acid ring acts as a UV chromophore.   
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Figure 2.2.  Internal and External Tautomers of Tetramic Acids. 
 
 
Biological Evaluation 
 
Ultimately, eleven tetramic acid compounds were synthesized and tested against a small 
panel of clinically relevant bacteria:  Staphylococcus aureus (methicillin-susceptible),  
Enterococcus faecalis, and Bacillus anthracis.  No Gram-negative bacteria were tested, 
as tetramic acids are generally inactive against them.  This is most likely due to a lack of 
penetration of the outer membrane of Gram-negative bacteria, although, a few exeptions 
to this trend have been noted;1,2,23 consequently, Gram-negative bacteria would not be 
expected to serve as reliable negative controls.  Tables 2.1 and 2.2 illustrate the structure-
activity relationship of the current series, with compounds 867 and 1138 included as a 
comparison of the compounds with the strongest activity from the prior series.1,2 
 
Among the compounds with the Boc protecting group, the predicted activity trends were 
nearly the opposite of the outcome.  The biphenyl and myrtenyl functional groups of 4a 
and 4b conferred essentially no activity against S. aureus or E. faecalis, although 4a had 
moderate activity against B. anthracis.  The other compounds possessed greater activity 
against all the bacteria tested, although the N-decyl group (4c), surprisingly, averaged no 
more potency than the aromatic compounds (4d-e).  These findings are in contrast to the 
findings of the earlier study,1,2 in which the myrtenyl and decyl N-substituents offered 
among the greatest potency.   
 
The primary amine compounds (Table 2.2) had greater activity than the Boc-protected 
compounds in the majority of cases, although it should be noted that the deprotected 
compounds typically had lower purity due to some remaining starting materials.  As with 
the parent series,1,2 unlike with the Boc-protected class, the most effective compounds 
possessed a bicyclic ring derived from myrtenyl (5b) or a long-chain alkyl group at N-1 
(5c).  Although the presence of a primary amine imparted generally greater activity 
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Table 2.1:  Structures and Activities of Tetramic Acids. 
 
General Structure No. R1 R2 
MIC (µg/mL) Mol. 
 Wt. CLogP MSSA EF BA 
R2
N
R1
O
O
OH
*
 
867† 
9  0.4 1.6 0.8 239.31 6.50 
1138†  1.6 1.6 0.8 331.45 5.42 
4a 
 
O
O
HN  
200 >200 25 478.58 5.06 
4b O O
HN
>200 >200 >200 446.58 4.89 
4c 
9
O
O
HN
50 25 6.25 452.63 6.49 
4d  O
O
HN
25 50 12.5 430.54 4.20 
4e O  O
O
HN
12.5 12.5 50 432.51 3.09 
 
MIC:  Minimum inhibitory concentration.  MSSA:  Methicillin-susceptible Staphylococcus aureus 8325; EF:  Enterococcus faecalis 
ATCC 33186; BA:  Bacillus anthracis Sterne 34F2.  Mol. Wt.:  Molecular weight.  CLogP was calculated using ChemDraw Ultra, 
Version 7.0 software by Cambridge Soft.   
†Source: Yendapally, R.; Hurdle, J. G.; Carson, E. I.; Lee, R. B.; Lee, R. E., N-Substituted 3-acetyltetramic acid derivatives as 
antibacterial agents. J. Med. Chem. 2008, 51, (5), 1487-1491.1                                                                                                                                            
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Table 2.2.  Structures and Activities of Tetramic Acids. 
 
General Structure No. R1 2 
MIC (µg/mL) Mol. 
Wt. CLogP MSSA EF BA 
R2
N
R1
O
O
OH
*
 
867† 
9  0.4 1.6 0.8 239.31 6.50 
1138†  1.6 1.6 0.8 331.45 5.42 
5a  H2N  100 200 12.5 378.46 3.31 
5b H2N  25 25 25 346.46 3.66 
5c 
9 H2N  25 25 25 352.51 4.75 
5d H2N >200 200 12.5 330.42 2.46 
5e O H2N 200 25 200 332.39 1.35 
6 
HO
25 12.5 25 381.46 4.71 
 
MIC:  Minimum inhibitory concentration.  MSSA:  Methicillin-susceptible Staphylococcus aureus 8325; EF:  Enterococcus faecalis 
ATCC 33186; BA:  Bacillus anthracis Sterne 34F2.  Mol. Wt.:  Molecular weight.  CLogP was calculated using ChemDraw Ultra, 
Version 7.0 software by Cambridge Soft. 
†Source:  Yendapally, R.; Hurdle, J. G.; Carson, E. I.; Lee, R. B.; Lee, R. E., N-Substituted 3-acetyltetramic acid derivatives as 
antibacterial agents. J. Med. Chem. 2008, 51, (5), 1487-1491.1
relative to the Boc-protected compounds, the effect was less pronounced for the 
compounds with N-1 benzylic substitution (5a, 5d-e).  With respect to the bacterial 
species, the compounds as a whole tended to be most effective against Bacillus anthracis, 
but the activity trends were generally similar for each of the three bacterial species tested. 
 
Hemolytic trends were far clearer than antibacterial activity trends (Figure 2.3); at the 
highest concentration of compound used (100 µg/mL), the primary amino lysine-derived 
compounds were, as hypothesized, less hemolytic than the Boc-protected compounds 
(except in the case of the 4-ethylbenzyl pair 4d and 5d).  At lower concentrations, the 
hemolytic activities were considerably more similar for the protected and deprotected 
pairs.  A similar statement can be made for compound 6; namely, that despite its lack of a 
basic functional group that has potential for carrying a positive charge, the presence of a 
hydrogen bond donor may be sufficient for reducing erythrocyte lysis without apparent 
loss of antimicrobial activity.   
 
A comparison between the current series and the earlier series illustrates some significant 
changes.  The antimicrobial activities of the present compounds, which possess polar 
functionalities at C-5, are considerably lower than the earlier compounds 867 and 11381,2 
possessing an isobutyl substituent at C-5 (Table 2.1).  However, a comparison between 
the present and previous compounds reveals a dramatic reduction in hemolysis at 100 
µg/mL (Figure 2.3).  The reduced antimicrobial activities of these molecules may be 
explainable in terms of reduced affinity for the membrane by the lipophilic N-functional 
groups.  The free-amino compounds should be, hypothetically, amphipathic due to the 
acidic diketone paired with basic primary amine.  In all instances, the lipophilic N-
substituent is likely to partition into the Gram-positive bacterial plasma membrane, 
whether the tetramic acid has an overall neutral or negative charge.  If the ring is 
amphipathic, however, the N-substituent’s position in the membrane becomes less 
energetically stable due to positive interactions with the membrane’s prevalent internal 
negative charges, and the tetramic acid is less able to maintain the position it requires for 
its depolarization of the membrane.   
 
It may appear that reduction of hemolytic activity is incompatible with improvement of 
antibacterial activity.  However, the mechanism of action on red blood cells membranes 
is thought to be different from that on bacterial in that bacteria rely on membrane 
potential difference for energy, whereas eukaryotic cells rely on mitochondria; therefore, 
ionophores would be expected to have weaker effects on eukaryotic cells.  Also, it has 
been suggested that hemolysis stems from membrane solubilization rather than 
ionophoric activity.  As such, there is potential for designing tetramic acids with selective 
activity, which could translate to clinically safe antimicrobials. 
 
 
Conclusions 
 
The chosen synthetic route led to the successful synthesis of several tetramic acids with a 
polar functional group at the C-5 position.  The hemolytic activity of the compounds 
synthesized was, as hypothesized, lowered due to the inclusion of a polar substituent at 
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Figure 2.3.  Hemolysis Chart. % Hemolysis:  Measured as optical density at 540 nm of supernatant of suspended erythrocyte 
samples to which a quantity of drug sufficient to provide the necessary concentration had been added and incubated.  Negative 
controls were non-hemolytic antibiotics ampicillin and doxycycline; positive control was Triton-X (induced 100% hemolysis).
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C-5.  Their antimicrobial activity, however, was weakened, potentially for the same 
reason.  Possible ways of increasing the antimicrobial potency may include alkylation of 
the free amino compounds to improve lipophilicity and penetration into bacterial 
membranes.  Also, as compound 6 exhibited antimicrobial activity comparable to several 
of the free amino compounds, and fairly low hemolytic activity, the synthesis of other 
compounds with similar polar but nonbasic substitution may merit further investigation.  
Future studies will be required to expand the tetramic acid series, maintaining low 
hemolytic activity while increasing antimicrobial activity. 
 
 
Experimental Section 
 
 
Chemistry 
 
General Synthetic Scheme 
 
Amino acid (N-Boc L-lysine or L-tyrosine) methyl ester hydrochloride was N-substituted 
by reductive amination with aldehydes 1a-e and Et3N in anhydrous THF in the presence 
of MgSO4 to maintain anhydrous conditions.  The resulting imine intermediates were 
reduced with NaBH4 in methanol.  The resulting secondary amines 2a-f were acylated 
with diketene in CH2Cl2 at reflux, employing Et3N in catalytic amount.  To form the 
tetramic acid rings, the acetoacetyl amides 3a-f were cyclized via Lacey-Dieckman 
condensation26 with sodium or potassium t-butoxide in t-butanol (these bases were 
chosen for their reduced tendency to cause isomerization).  These tetramic acids 4a-f 
were tested for antimicrobial activity.  For further testing, the Boc group was removed 
from the N-Boc lysine-derived tetramic acids with TFA in THF to form primary amines 
5a-e as their TFA salts.  The TFA cleavage step proved to be the most difficult, with 
incomplete reaction being the norm and frequently necessitating a second trial before MS 
testing demonstrated the disappearance of the starting material. 
 
 
Experimental Methods 
 
1H NMR was performed on either a Varian Unity INOVA 500 MHz spectrometer or a 
Bruker-ARX 300 MHz spectrometer.  Mass spectra were recorded on a Bruker-Esquire 
LC-MS using ESI.  Flash chromatography was performed on a Biotage Horizon HPFC 
system, employing Biotage FLASH 25 + M cartridges.  Yields quoted are unoptimized.  
HPLC1, HPLC2, HPLC3, and HPLC4 methods were followed using a Phenomenex 
platinum C-18 reverse phase column (100Å, 50 x 4.6 mm) at ambient temperature, and a 
flow rate of 1.0 mL min-1. HPLC1: Gradient: solvent A (0.1% TFA in water) and solvent 
B (acetonitrile): 0-2.00 min. 100% A, 2.00-7.00 min. 0-100% B (linear gradient), 7.00-
8.00 min. 100% B, 8.00-9.90 min. 100-0%B (linear gradient), 9.90-10.00 min. 0%B, UV 
detection at 254 nm.  HPLC2: Gradient: solvent A (0.1% TFA in water) and solvent B 
(acetonitrile): 0-1.00 min 0-80% B (linear gradient), 1.00-7.5 min 80%-100% B (linear 
gradient), 7.5-8.00 min 100% B, 8.00-9.00 min. 100-0% B (linear gradient), 9.00-10.00 
26 
min. 100% A, UV detection at 254 nm.  HPLC3:  Gradient:  solvent A (0.1% TFA in 
water) and solvent B (acetonitrile):  0-2.00 min 35%B, 2.00-7.00 min 35-100%B (linear 
gradient), 7.00-8.00 min 100%B, 8.00-9.00 min 100-35%B (linear gradient), 9.00-10.00 
min 35%B, UV detection at 254 nm.  HPLC4:  Gradient:  solvent A (0.1% TFA in water) 
and solvent B (acetonitrile):  0-2.00 min 100%A, 2.00-17.00 min 0-100%B (linear 
gradient), 17.00-18.00 min 100%B, 18.00-19.90 min 100-0%B (linear gradient), 19.90-
20.00 min 0%B, UV detection at 254 nm. 
 
Solvents were purchased from Sigma-Aldrich and Fisher and used without further 
purification.  All reagents were provided by Sigma-Aldrich, except for L-tyrosine methyl 
ester, which was provided by EMD Biosciences. 
 
General procedure for preparation of secondary amines (2a-d.)  The L-amino acid 
methyl ester hydrochloride salt (1 equiv) was dissolved in anhydrous THF, and to it were 
added aldehyde (2 equiv), Et3N (1 equiv), and MgSO4 (1.7 equiv).  The mixture was 
allowed to stir at room temperature under argon for a minimum of 6 h, then filtered and 
evaporated in vacuo to yield the crude imine.  The crude imine was directly dissolved in 
methanol, and to it was slowly added NaBH4 (2 equiv).  The reaction mixture was 
quenched with excess 1 N NaOH and extracted with ethyl acetate, then dried over 
Na2SO4 and concentrated in vacuo.  The crude secondary amine was then purified by 
flash chromatography via a petroleum ether/ethyl acetate gradient. 
 
6-tert-Butoxycarbonylamino-2-(4-phenyl-benzylamino)-hexanoic acid methyl ester 
(2a).  To a solution of L-lysine methyl ester hydrochloride (0.5 g, 1.68 mmol) in 
anhydrous THF (10 mL) were added biphenyl-4-carboxaldehyde (0.614 g, 3.37 mmol), 
Et3N (235 μL, 1.68 mmol), and MgSO4 (0.345 g, 2.86 mmol), and left to stir at rt under 
argon overnight.  The reaction mixture was filtered, then concentrated in vacuo to yield 
the crude imine.  The crude imine was then dissolved in methanol, and NaBH4 (0.127 g, 
3.37 mmol) added to it slowly.  The mixture was stirred at rt for 30 min, then quenched 
with excess 1 N NaOH and extracted with ethyl acetate, then worked up as in the general 
procedure to yield 0.531 g (73.9%) of 2a as syrup.  1H NMR (500 MHz, CD3OD):  δ 1.24 
(1H, t, J = 7.25 Hz), 1.32-1.41 (2H, m), 1.41-1.49 (11H, m), 1.62-1.71 (2H, m), 2.01 (1H, 
s), 3.02 (2H, t, J = 6.25 Hz), 3.29 (1H, t, J = 7.75 Hz), 3.65 (1H, d, J = 13.5 Hz), 3.71 
(3H, s) 3.80 (1H, d, J = 13 Hz), 4.10 (1H, q, J = 7.17 Hz) 7.30-7.34 (1H, t, J = 7.25 Hz), 
7.38-7.44 (4H, dd, J = 7.67 Hz), 7.55-7.61 (4H, dd, J = 7.5 Hz).  ESI-MS:  449.3 (M + 
23). 
 
6-tert-Butoxycarbonylamino-2-[(6-methyl-bicyclo[3.1.1]hept-2-en-2-ylmethylene)-
amino]-hexanoic acid methyl ester (2b).  To a solution of L-lysine methyl ester 
hydrochloride (0.40 g, 1.35 mmol) in anhydrous THF (10 mL) were added (1R)-(-)-
myrtenal (410 μL, 2.70 mmol), Et3N (225 μL, 1.62 mmol), and MgSO4 (0.276 g, 2.29 
mmol), and left to stir at rt under argon for 10.5 h.  The reaction mixture was filtered, 
then concentrated in vacuo to yield the crude imine.  The crude imine was dissolved in 10 
mL methanol, then 0.102 g NaBH4 (2.70 mmol) was added slowly.  The mixture was 
stirred at rt for 30 min, then worked up as described in the general procedure to yield 0.21 
g (39.5%) of 2b.  1H NMR (500 MHz, CDCl3):  δ 0.83 (3 H, s), 1.14 (1H, d, J = 9Hz), 
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1.27-1.31 (4.4H, m), 1.34-1.40 (2.37H, m), 1.41-1.52 (11.88H, m), 1.54-1.67 (2.28H, m), 
1.67-1.72 (1.14H, s), 2.09 (2H, d, J = 5Hz), 2.18-2.24 (2H, q, J = 17.3Hz), 2.34-2.39 
(1.06H, m), 2.95 (1H, d), 3.07-3.11 (3H, m), 3.24 (1H, t), 3.72 (3H, s), 4.66 (0.83H, s), 
5.36 (1H, s).  ESI-MS:  395.3 (M + 1), 417.3 (M + 23). 
 
6-tert-Butoxycarbonylamino-2-decylamino-hexanoic acid methyl ester (2c).  To a 
solution of L-lysine methyl ester hydrochloride (0.91 g, 3.1 mmol) and MgSO4 (0.50 g, 
4.2 mmol) in anhydrous THF (25 mL) were added decanal (0.38 mL, 2.0 mmol), and 
Et3N (0.59 mL, 4.2 mmol), and the reaction was left to stir at rt .  The reaction mixture 
was filtered, then concentrated in vacuo to yield the crude imine.  The crude imine was 
then dissolved in methanol, and NaBH4 (0.153 g, 4.04 mmol) added to it slowly.  The 
mixture was stirred at rt for 30 min, quenched with excess 1 N NaOH and extracted with 
ethyl acetate, then worked up as described in the general procedure to yield 0.671 g 
(82.9%) of 2c.  1H NMR (500 MHz, CDCl3):  0.88 (3H, t, J = 6.5 Hz), 1.18-1.33 
(13.94H, m), 1.32-1.40 (1.8H, m), 1.38-1.53 (11.94H, m), 1.57-1.68 (2.17H, m), 2.41-
2.48 (1 H, m), 2.50-2.58 (1H, m), 3.04 (1.15H, s), 3.05-3.14 (1.71H, m), 3.20-3.26 (1H, t, 
J = 6.25Hz), 3.72 (3H, s), 4.87 (1H, bs).  ESI-MS:  401.4 (M + 1), 423.3 (M + 23).   
 
6-tert-Butoxycarbonylamino-2-(4-ethyl-benzylamino)-hexanoic acid methyl ester 
(2d).  To a solution of L-lysine methyl ester hydrochloride (0.40 g, 1.35 mmol) in 
anhydrous THF (10 mL) were added 4-ethylbenzaldehyde (369 μL, 2.70 mmol), Et3N 
(188 μL, 1.68 mmol), and MgSO4 (0.276 g, 2.29 mmol), and left to stir at rt under argon 
for 9 h.  The reaction mixture was filtered, then concentrated in vacuo to yield the crude 
imine.  The crude imine was then dissolved in methanol (10 mL), and NaBH4 (0.1-2 g, 
2.70 mmol) added to it slowly.  The mixture was stirred at rt for 30 min, then quenched 
with 7 mL of 1 N NaOH and extracted with 3 x 10 mL ethyl acetate, then worked up as 
described in the general procedure to yield 0.248 g (48.6%) of 2d as gel.  1H NMR (500 
MHz, CD3OD):  δ 1.28 (3H, t), 1.34-1.41 (2.41H, m), 1.41-1.56 (11.19H, m), 1.67-1.77 
(2H, m), 2.66-2.71 (2H, q), 3.06-3.10 (2H, t), 3.31-3.35 (1H, t), 3.64-3.67 (1H, d), 3.77 
(3H, s), 3.77-3.81 (1H, d), 7.20-7.23 (2H, d), 7.28-7.31 (2H, d).  ESI-MS:  401.3 (M + 
23). 
 
6-tert-Butoxycarbonylamino-2-(4-methoxy-benzylamino)-hexanoic acid methyl ester 
(2e).  To a solution of L-lysine methyl ester hydrochloride (0.40 g, 1.35 mmol) in 
anhydrous THF (15 mL) were added p-anisidine (367 μL, 3.02 mmol), Et3N (188 μL, 
1.35 mmol), and MgSO4 (0.276 g, 2.29 mmol), and left to stir at rt under argon for 6.25 h.  
The reaction mixture was filtered, then concentrated in vacuo to yield the crude imine.  
The crude imine was then dissolved in methanol (15 mL), and NaBH4 (0.102 g, 2.70 
mmol) added to it slowly.  The mixture was stirred at rt for 30 min, then 0.050 g 
additional NaBH4 added slowly, and the mixture stirred for an additional 1 h.  The 
reaction was then quenched with excess 1 N NaOH.  Ethyl acetate was added, then the 
mixture was evaporated to dryness, then reconstituted with methanol, water, and ethyl 
acetate.  The cloudy precipitate in the aqueous layer was drained off, then more water 
added, and the precipitate drained off again.  Finally, the solution was extracted with 
ethyl acetate, allowing the precipitate to settle out of the organic layer, and the material 
worked up as in the general procedure to yield 0.152 g (29.8%) of 2e.  1H NMR (300 
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MHz, CD3OD):  1.23-1.53 (12.49H, m), 1.59-1.73 (1.79H, m), 2.94-3.10 (1.72H, m), 
3.26 (0.83H, t, J = 11.2Hz), 3.52-3.68 (1.09H, m), 3.69 (0.75H, s), 3.73 (2.11H, s), 3.78-
3.88 (2.90H, m), 6.83-6.99 (1.92H, m), 7.16-7.40 (2H, m).  ESI-MS:  487.3 (M + 23) 
 
2-[(6,6-Dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-amino]-3-(4-hydroxy-phenyl)-
propionic acid methyl ester (2f).  To a solution of L-tyrosine methyl ester hydrochloride 
(0.60 g, 2.6 mmol) and MgSO4 (0.778 g, 4.2 mmol) in anhydrous THF (15 mL) were 
added (1R)-(-)-myrtenal (0.79 mL, 5.2 mmol), and Et3N (0.43 mL, 3.1 mmol), and the 
reaction was left to stir at rt for 5 h.  The reaction mixture was filtered, then concentrated 
in vacuo to yield the crude imine.  The crude imine was then dissolved in 15 mL 
methanol, and NaBH4 (0.196 g, 5.18 mmol) added to it slowly.  The mixture was stirred 
at rt for 30 min, then quenched with 10 mL 1 N NH4Cl, concentrated under reduced 
pressure, reconstituted with 10 mL water, and extracted with 3 x 25 mL ethyl acetate, 
then worked up as in the general procedure to yield 0.576 g (67.5%) of 2f.  1H NMR (500 
MHz, CD3OD):  δ 0.82 (0.19H, s), 0.84 (3H, s), 1.14 (1H, d, J = 8.5 Hz), 1.27 (0.19H, s), 
1.29 (3H, s), 2.05-2.11 (2H, m), 2.21-2.32 (2H, q, J = 14.8 Hz), 2.37-2.43 (1H, m), 2.86 
(2H, d, J = 6.5 Hz), 2.98 (1H, d, J =  14 Hz),  3.11 (1H, d, J = 13.5 Hz), 3.37 (2H, s), 3.49 
(1H, t, J = 7 Hz), 3.63 (3H, s), 3.66 (0.17H, s), 5.34 (1H, s), 6.72 (2H, d, J = 8 Hz), 6.99 
(2H, d, J = 9 Hz).  ESI-MS: (+) 330.3 (M + 1), 352.2 (M + 23); (-) 328.0 (M - 1). 
 
General procedure for N-acetoacetyl amino esters (3a-f).  Secondary amine (2a-f) was 
dissolved in CH2Cl2, to which 1 equivalent of 50% diketene in CH2Cl2 and 5 drops Et3N 
were added.  The mixture was allowed to reflux at 45°C for a minimum of 5 h, then 
allowed to cool to rt and diluted with CH2Cl2, acidified with 1 N HCl, and extracted.  The 
organic layer was rinsed with water, dried with Na2SO4, filtered, and concentrated in 
vacuo.  The crude product was purified via flash chromatography, employing a petroleum 
ether/ethyl acetate gradient. 
 
6-tert-Butoxycarbonylamino-2-[(4-phenyl-benzyl)-(3-oxo-butyryl)-amino]-hexanoic 
acid methyl ester (3a).  To a solution of 2a (0.531 g, 1.24 mmol) in dichloromethane 
were added 50% diketene in dichloromethane (210 μL, 1.24 mmol) and 5 drops of Et3N.  
The mixture was allowed to reflux at 45°C overnight, then allowed to cool, diluted with 
20 mL dichloromethane, quenched with 1 N HCl, and then the organic component 
washed twice with water before being worked up as in the general procedure to yield 
0.502 g (79.0%) of 3a as syrup.  1H NMR (500 MHz, CD3OD):  δ 1.18-1.48 (13.12H, m), 
1.70-1.86 (1H, m), 1.88 (1H, s), 1.93-2.10 (1.43H, m), 2.20 (1.13H, s), 2.3 (0.48H, s), 
2.86-3.05 (2H, m), 3.37 (1.45H, s), 3.49-3.55 (0.73H, m), 3.60 (2.22H, d, J = 10.5Hz), 
3.63-3.82 (0.89H, m), 4.37-4.51 (0.58H, m), 4.53-4.76 (2.35H, m), 4.85 (2.29H, s), 5.28-
5.31 (0.32H, s), 7.30-7.48 (5H, m), 7.52-7.69 (4H, m).  ESI-MS:  533.3 (M + 23). 
 
6-tert-Butoxycarbonylamino-2-[1-(6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-yl)-2,4-
dioxo-pentylamino]-hexanoic acid methyl ester (3b).  To a solution of 2b (0.210 g, 
0.402 mmol) in dichloromethane (10 mL) were added 50% diketene in dichloromethane 
(89.5 μL, 0.402 mmol) and 5 drops of Et3N.  The mixture was allowed to reflux at 45°C 
for 5 h, then allowed to cool to room temperature prior to adding 20 mL CH2Cl2, then 10 
mL of 1 N NaOH, followed by 20 mL 1 N HCl.  The organic layer was separated and 
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washed with 2 x 10 mL water, and then, the combined aqueous portions were back 
extracted with 2 x 20 mL CH2Cl2.  The organic layers were then worked up as in the 
general procedure to afford 0.12 g (47.1%) of 3b as a colorless oil.  1H NMR (500 MHz, 
CDCl3):  δ 0.83 (3H, d, J = 9 Hz), 1.12 (1.05H, t, J = 9.25 Hz), 1.24-1.27 (0.47H, d, J = 6 
Hz), 1.29 (3H, s), 1.33-1.43 (2.10H, m), 1.41-1.47 (9.27H, m), 1.47-1.54 (2.15 H, m), 
1.67-1.78 (1.87H, m), 1.90-1.99 (2.93H, m), 2.11-2.16 (1H, bs), 2.17 (0.77H, s), 2.2-2.34 
(3.68, m), 2.38-2.44 (1H, m), 3.06-3.15 (2H, bs), 3.52-3.54 (1.33H, s), 3.55-3.63 (0.95H, 
m), 3.68 (3H, s), 3.69-3.72 (0.38H, d, J = 11.5 Hz), 3.81-3.90 (0.94H, m), 4.68 (0.66H, t, 
J = 7 Hz), 4.77-4.82 (0.29H, t, J = 7 Hz), 5.02 (0.32H, s), 5.32-5.37 (0.30, bs), 5.38-5.43 
(0.62, bs).  ESI-MS:  501.2 (M + 23). 
 
6-tert-Butoxycarbonylamino-2-[decyl-(3-oxo-butyryl)-amino]-hexanoic acid methyl 
ester (3c).  To a solution of 2c (0.671 g, 1.68 mmol) in dichloromethane (35 mL) were 
added 50% diketene in dichloromethane (0.28 mL, 1.68 mmol) and 10 drops of Et3N.  
The mixture was allowed to reflux at 45°C for 7 h, then allowed to cool to rt, and diluted 
with 40 mL CH2Cl2.  To the mixture was added 10 mL of 1 N HCl; the aqueous and 
organic layers were separated and the organic layer washed with 2 x 20 mL water.  The 
combined aqueous layers were then back extracted with 2 x 40 mL CH2Cl2. The reaction 
mixture was then worked up as in the general procedure to yield 0.463 g (57.0%) of 3c as 
a yellow amorphous solid.  1H NMR (500 MHz, CDCl3):  δ 0.69-0.77 (3H, t, J = 7 Hz), 
1.02-1.42 (28.34H, m), 1.42-1.76 (1.09H, m), 1.76-1.83 (1H, s), 1.83-1.97 (1.08H, m), 
2.07 (0.77H, s), 2.11 (2H, s), 2.86-3.04 (2.23H, m), 3.10-3.22 (0.89H, m), 3.31-3.48 
(1.34H, m), 3.48-3.60 (3.18H, m), 3.78-3.83 (0.44H, bs), 4.05-4.20 (0.58H, m), 4.41-4.52 
(0.22H, m), 4.79-4.95 (0.80H, m).  ESI-MS:  507.3 (M + 23). 
 
6-tert-Butoxycarbonylamino-2-[(4-ethyl-benzyl)-(3-oxo-butyryl)-amino]-hexanoic 
acid methyl ester (3d).  To a solution of 2d (0.248 g, 0.655 mmol) in dichloromethane 
(12 mL) were added 50% diketene in dichloromethane (111 μL, 0.655 mmol) and 5 drops 
of Et3N.  The mixture was allowed to reflux at 45°C for 7 h, then allowed to cool and 
diluted with 15 mL CH2Cl2, then washed with 5 mL of1 N HCl, followed by 2 x 10 mL 
H2O.  The material was then worked up as in the general procedure.  The material was 
then reacted again, employing 90 µL (0.046 g, 0.545 mmol), of 50% diketene in 
dichloromethane, several drops of Et3N, and 10 mL dichloromethane; the reaction 
refluxed at 45°C for 10h, then cooled and diluted with 20 mL CH2Cl2 and washed with 
10 mL 1 N HCl, followed by 2 x 10mL H2O and worked up as in the general procedure 
without chromatography to give 3d in an overall yield of 0.186 g (61.4%).  1H NMR (500 
MHz, CD3OD):  1.20-1.30 (3.69H, m), 1.30-1.44 (3.22H, m), 1.50 (9.42H, d, J = 28Hz), 
1.68-1.85 (1.17H, m), 1.91 (0.63H, s), 1.95-2.09 (1H, m), 2.21 (1.18H, s), 2.31 (0.44H, 
s), 2.60-2.71 (2H, m), 2.88-3.08 (2H, m), 3.53 (0.57H, s), (1.9H, ), 3.65-3.74 (0.50H, m), 
3.75 (0.49H, s), 3.76-3.93 (0.31H, m),4.35-4.41 (0.42H, m) 4.46-4.72 (2.27H, m), 5.32 
(0.13H, s), 6.36-6.52 (0.50H, m), 7.12-7.32 (4H, m).  ESI-MS:  485.3 (M + 23). 
 
6-tert-Butoxycarbonylamino-2-[(4-methoxy-benzyl)-(3-oxo-butyryl)-amino]-
hexanoic acid methyl ester (3e).  To a solution of 2e (0.152 g, 0.399 mmol) in 
dichloromethane (10 mL) were added 50% diketene in dichloromethane (67 μL, 0.399 
mmol). The mixture was allowed to reflux at 45°C for 18 h; then, 13 drops of Et3N and 
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an additional 67 µL diketene were added, and the reaction refluxed a further 24h at 45°C, 
then allowed to cool to near room temperature.  10 mL of 1 N HCl were added to the 
mixture, then 20 mL CH2Cl2.  The organic layer was separated and washed with 2 x 10 
mL water, then worked up as in the general procedure to afford 0.186 g (61.4%) of 3e.  
1H NMR (500 MHz):  δ 1.10-1.54 (12.34H, m), 1.68-1.84 (0.93H, m), 1.90 (0.81H, s), 
1.93-2.08 (1.2H, m), 2.13-2.32 (2.2H, m), 2.57-2.63 (0.5H, m), 2.87-3.02 (1.67H, m), 
3.32-3.35 (0.5H, m), 3.37 (0.45H, s), 3.50-3.54 (0.47H, s), 3.56-3.63 (1.64H, m), 3.63-
3.75 (0.89H, m), 3.75-3.89 (3.56H, m), 4.27-4.33 (0.34H, m), 4.38-4.64 (2.13H, m), 4.85 
(2.45H, s), 4.90-5.04 (0.31H, m), 6.75-6.98 (2.1H, m), 7.16-7.34 (2H, m).  ESI-MS:  
487.3 (M + 23). 
 
2-[(6,6-Dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-(3-oxo-butyryl)-amino]-3-(4-
hydroxy-phenyl)-propionic acid methyl ester (3f).  To a solution of 2f (0.576 g, 1.75 
mmol) in anhydrous CHCl3 (30 mL) were added 50% diketene in dichloromethane (296 
µL, 1.76 mmol) and several drops of Et3N.  The reaction was refluxed at 45°C for 9 h, 
then allowed to cool to rt, diluted with 40 mL CHCl3 and extracted with 10 mL water 
combined with 10 mL of 1 N HCl solution.  The aqueous layer was extracted with 2 x 40 
mL CHCl3, and the combined organic layers worked up as in the general procedure to 
yield 0.287 g (39.7%) 3f as a brown gel.  1H NMR (500MHz, CD3OD):  δ 0.82 (2.06H, 
s), 0.84 (0.68H, s), 0.87 (0.13H, s), 1.09-1.13 (0.93H, m), 1.30 (3H, s), 1.92 (0.60H, s), 
1.97-2.02 (0.88H, broad triplet, J = 5.25 Hz), 2.033 (0.12H, s), 2.06-2.10 (1.01H, bs), 
2.15 (0.12H, s), 2.19 (0.18H, s), 2.21 (2.19H, s), 2.22-2.25 (0.63H, bs), 2.27-2.30 (0.56H, 
bs), 2.30-2.34 (0.23H, bs), 2.38-2.44 (1 H, m), 2.99 (0.83H, d, J = 17 Hz), 3.03 (0.12H, 
s), 3.07-3.15 (1H, m), 3.17-3.26 (1H, m), 3.37 (4.45H, s), 3.51-3.62 (1.36H, q, J = 15.2 
Hz), 3.66 (0.62, s), 3.68 (2.09H, s), 3.70 (0.13H, s), 3.70-3.73 (0.48, bs), 3.74-3.77 
(0.44H, bs), 4.29 (0.69H, dd, J = 5.17 Hz), 5.13 (0.18H, s), 5.23 (0.24H, s), 5.30 (0.66, s), 
6.69-6.78 (1.89H, m), 7.01 (0.43H, d, J = 9Hz), 7.7.08 (1.48H, d, J = 8.5Hz).  ESI-MS:  
414.3 (M + 1), 436.3 (M + 23). 
 
General procedure for formation of tetramic acids 4b-e and 6.  To a flask containing 
the diketone, 5 mL warmed t-butanol was added.  The flask was kept at 40°C to prevent 
the solvent from solidifying, and to it was added 3 equivalents of either sodium or 
potassium tert-butoxide, gradually.  The reaction mixture was stirred for 1 h, then water 
and excess 1 N HCl solution were added.  The neutralized mixture was extracted with 
CH2Cl2, dried with Na2SO4, filtered, and concentrated in vacuo. 
 
(4-[1-(4-phenyl-benzyl)-4-(1-hydroxy-ethylidene)-3,5-dioxo-pyrrolidin-2-yl]-butyl)-
carbamic acid tert-butyl ester (4a).  A quantity of t-butanol was thawed, and was added 
to 0.283 g of sodium t-butoxide.  The base dissolved poorly in the solvent, but suspended 
solid was added via Pasteur pipet into a flask containing 0.502 g 3a, kept stirring at 40°C.  
Approximately half the base could be added to the reaction mixture; the amount of time 
spent in the addition was approximately 40 min.  To the reaction mixture was added 
water and 1 N HCl, and the mixture extracted with CH2Cl2.  Yield:  0.114 g, 24.2%. 
1H NMR (500MHz, CD3OD):  δ 1.24 (0.73H, s), 1.26-1.39 (2.40H, m), 1.43 (9.24H, s), 
1.72-1.80 (2H, m), 2.01 (0.29H, s), 2.46 (2.45H, s), 2.92-2.98 (2H, m), 3.37 (9.70H, s), 
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7.33 (1H, t, J = 7.25 Hz), 7.38-7.46 (4H, m), 7.58-7.63 (4H, m).  ESI-MS:  501.2 
(M+23).  HPLC1: 254 nm tR 7.13 min, purity 41%. 
(4-[1-(6,6-Dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-4-(1-hydroxy-ethylidene)-
3,5-dioxo-pyrrolidin-2-yl]-butyl)-carbamic acid tert-butyl ester (4b).  A portion of t-
butanol was thawed, and a quantity (5 mL) of it was added to 3b (0.109 g, 0.225 mmol).  
To this solution was added potassium t-butoxide (0.070 g, 0.724 mmol), slowly.  The 
reaction was stirred for 1 h at 40°C, then 8 mL water and 8 mL of 1 N HCl were added.  
The reaction was extracted with 3 x 20 mL CH2Cl2, then worked up as in the general 
procedure to yield 0.097 g (95.7%) of product as yellow gel.  1H NMR (500 MHz, 
CDCl3):  δ 0.78 (0.41H, s), 0.83 (3H, s), 1.02 (1H, d, J = 9 Hz), 1.07-1.16 (1.28H, m), 
1.22-1.30 (4.94, m), 1.40-1.52 (12.64H, m), 1.68-1.79 (1.14H, m), 1.84-1.94 (1.14H, m), 
1.97 (0.94H, t, J = 5 Hz), 2.03 (0.27H, s), 2.06-2.12 (1.24H, m), 2.18-2.22 (0.35H, m), 
2.22-2.25 (0.83H, m), 2.27-2.31 (0.79H, m), 2.31-2.37 (1.33H, m), 2.43 (2.64H, s), 2.52 
(0.41H, s), 3.00-3.15 (2.31H, m), 3.30 (0.81H, d, J = 14.5 Hz), 3.63-3.68 (0.82H, m), 
3.72-3.84 (0.29H, m), 4.11 (0.18H, q, J = 7.5Hz), 4.49-4.64 (2H, m), 5.39-5.48 (0.24H, 
m), 5.50 (0.85H, s). ESI-MS:  (+) 469.2 (M + 23), (-) 445.1 (M - 1).  HPLC2:  254 nm tR 
3.20 min, purity 99%.   
 
(4-[1-Decyl-4-(1-hydroxy-ethylidene)-3,5-dioxo-pyrrolidin-2-yl]-butyl)-carbamic 
acid tert-butyl ester (4c).  A portion of t-butanol was thawed, and a quantitiy (8 mL) of 
it was added to 3c (0.442 g, 0.912 mmol).  To this solution was added potassium t-
butoxide (0.307 g, 2.74 mmol), slowly.  The reaction was stirred for 2 h at 35°C, then 20 
mL water and 20 mL of 1 N HCl were added.  The solution was extracted with 40 mL, 
then 3 x 30 mL CH2Cl2, then worked up as in the general procedure to yield 0.405 g 
(98.3%) of product as dark brown oil.  1H NMR (500 MHz, CDCl3):  δ  0.83 (3H, t, J = 7 
Hz), 1.03-1.14 (1.28H, m), 1.14-1.32 (14.1H, closely spaced uneven peaks), 1.34-1.61 
(10.75Hz, two single peaks among a multiplet), 1.66-1.75 (0.76H, m), 1.84-1.96 (0.84H, 
m), 1.99 (0.17H), 2.17 (0.5H, s), 2.27 (0.17H, t, J = 7.5 Hz), 2.38 (2H, s), 2.47 (0.23H, 
bs), 2.83-3.08 (2.05H, m), 3.58-3.65 (0.39H, m), 3.73-3.83 (1.38H, m), 3.86-3.96 (0.41H, 
m), 4.70 (0.39H, bs).  ESI-MS:  475.3 (M + 23).  HPLC2:  254 nm tR 4.38 min, purity 
79%. 
 
(4-[1-(4-Ethyl-benzyl)-4-(1-hydroxy-ethylidene)-3,5-dioxo-pyrrolidin-2-yl]-butyl)-
carbamic acid tert-butyl ester (4d).  A portion of t-butanol was thawed, and a quantity 
(5 mL) of it was added to 3d (0.186 g, 0.402 mmol).  To this solution was added sodium 
t-butoxide (0.116 g, 1.206 mmol), slowly.  The reaction was stirred for 1.5 h at 40°C, 
then 10 mL 1 N HCl was added.  The solution was extracted with 3 x 25 mL CH2Cl2, 
then worked up as in the general procedure to yield 0.078 g (43.9%) of product as dark 
orange oil.  1H NMR (500 MHz):  0.92 (0.37H, q, J = 7 Hz), 1.00-1.11 (1H, m), 1.11-
1.18 (0.81H, m), 1.21 (3H, t, J = 7.5 Hz), 1.24 (0.52H, s), 1.29 (0.5H, s), 1.30-1.41 
(1.69H, m), 1.44 (6.37H, s), 1.47 (1.78H, s), 1.50 (0.41H, d, J = 6.5 Hz), 1.69-1.89 
(1.89H, m), 2.21 (0.66H, s), 2.44 (2.32H, s), 2.62 (2H, q, J = 7.5 Hz), 2.94 (1.27H, m), 
3.33 (0.29H, s), 3.37 (2H, s), 3.59 (0.42H, t, J = 6.25 Hz), 3.97 (0.42H, q, J = 12.5 Hz), 
4.26 (0.81H, t, J = 14 Hz), 4.92 (1H, dd, J1 = 15 Hz, J2 = 5.5 Hz), 5.03 (2.92H, bs), 7.18 
(2H, d, J = 7.5 Hz), 7.24 (2H, d, J = 7.5 Hz) ESI-MS:  (+) 485.3 (M + 23), (-) 451.1 (M – 
1).  HPLC1:  254 nm tR 7.25 min, purity 84%.   
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(4-[4-(1-Hydroxy-ethylidene)-1-(4-methoxy-benzyl)-3,5-dioxo-pyrrolidin-2-yl]-
butyl)-carbamic acid tert-butyl ester (4e).  A portion of t-butanol was thawed, and a 
quantity (5 mL) of it was added to 3e (0.112 g, 0.241 mmol).  To this solution was added 
sodium t-butoxide (0.070 g, 0.724 mmol), slowly.  The reaction was stirred for 1 h, then 8 
mL water and 1 N HCl were added.  The solution was extracted with 3 x 25 mL CH2Cl2, 
then worked up as in the general procedure to give the product in quantitative yield 
(0.108 g).  1H NMR (500 MHz, CD3OD):  δ 0.80-0.87 (0.62H, q, J = 9 Hz), 0.90-1.13 
(2.0H, m), 1.16 (1.37H, s), 1.18-1.42 (11.78H; m, but with a singlet at 1.352), 1.62-1.80 
(1.94H, m), 2.13 (0.20,H, s), 2.20 (0.22H, s), 2.36 (2.22H, s), 2.82-2.90 (1.67H, m), 3.24 
(0.58H, quintet, J = 1.5 Hz), 3.28 (0.92H, s), 3.63 (0.73H, bs), 3.70 (3H, s), 4.11 (0.73H, 
d, J = 14.5 Hz), 4.45 (0.30H, s), 6.78-6.84 (2H, m), 7.13-7.21 (2H, m).  ESI-MS:  (+) 
455.3 (M + 23), (-) 431.0 (M - 1).  HPLC1:  254 nm tR 6.74 min, purity 92%.  
 
1-(6,6-Dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-5-(4-hydroxy-benzyl)-3-(1-
hydroxy-ethylidene)-pyrrolidine-2,4-dione (6).  A portion of t-butanol was thawed, and 
a quantity (12 mL) of it was added to 3f (0.287 g, 0.693 mmol).  To this solution was 
slowly added sodium t-butoxide (0.233 g, 2.079 mmol).  The reaction was stirred for 1 h 
at 40°C, then 10 mL water and 10 mL of 1 N NaOH were added.  The reaction mixture’s 
pH was brought to approximately 4 with concentrated HCl solution and potassium t-
butoxide, then extracted with 3 x 60 mL CHCl3, then worked up as in the general 
procedure to give the product in quantitative yield.  1H NMR (500 MHz, CD3OD):  δ 0.81 
(0.77H, s), 0.87 (3H, s), 1.11 (1H, d, J = 8.5 Hz), 1.17 (0.29H, d, J = 8.5 Hz), 1.24 
(0.51H, s), 1.26 (1.19H, d, J = 1.5H), 1.27 (0.28H, s), 1.30 (3.16H, s), 1.96 (1H, broad 
triplet, J = 5 Hz), 2.03 (0.88H, s), 2.05-2.07 (0.27H, m), 2.07-2.13 (1.34H, m), 2.22-2.25 
(0.42H, m), 2.26-2.29 (1.27H, m), 2.30-2.33 (0.86H, m), 2.36 (4.20H, s), 2.37-2.46 
(1.28H, m), 2.98 (0.1H, d, J ≈ 4.5 Hz), 3.00 (0.5H, t, J = 4.2 Hz), 3.03 (0.7H, J = 4.5 Hz), 
3.08 (0.68H, J = 4.5H), 3.11 (0.50H, J = 4.2), 3.15 (0.12H, d, J ≈ 4.5 Hz), 3.37 (9.28H, 
s), 3.51 (0.61H, two close singlets), 3.58 (0.60H, two singlets), 3.92-3.96 (0.91H, bs), 
4.05-4.08 (0.23H, bs), 4.12 (0.61H, q, J = 7 Hz), 4.44-4.52 (1.26H, m), 5.32 (0.25H, s), 
5.42 (1.01H, s), 6.67 (2.47H, d, J = 8.5 Hz), 6.95 (2.48H, d, J = 8 Hz).  ESI-MS: 404.2 
(M + 23).  HPLC3: 254 nm, tR 5.90 min, Purity 98%.   
 
General procedure for primary amine formation from Boc-protected tetramic acids 
(5a-e).  To the corresponding tetramic acid (4a-e) was added THF, followed by 
approximately 0.5 equivalents TFA.  The solution was stirred for 1 h at rt, then 
evaporated to dryness.   
 
5-(4-Amino-butyl)-1-biphenyl-4-ylmethyl-3-(1-hydroxy-ethylidene)-pyrrolidine-2,4-
dione (5a).  To 0.114 g (0.238 mmol) of 4a were added 1 mL THF, followed by 1 mL 
TFA.  The mixture was stirred for 4 h at r. t., then evaporated.  The reaction was then 
repeated again with 1 mL THF and 1 mL TFA overnight, then evaporated to dryness.   
1H NMR (300 MHz, CDOD3):   0.99-1.33 (2.48H, m), 1.42 (2.33H, s), 1.45-1.64 (1.63H, 
m), 1.71-2.00 (1.94H, m), 2.47 (2.32H, s), 2.80 (1.31H, t, J = 6.75 H), 2.88-2.98 (0.37H, 
m), 3.32 (0.71H, s), 3.72-3.87 (0.72H, m), 4.26-4.44 (0.81H, m), 4.86-5.16 (5.73H, 
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closely spaced singlets), 7.23-7.49 (5.03H, m), 7.50-7.71 (4H, m), 7.84-7.92 (0.42H, m).  
ESI-MS:  379.2 (M + 1).  HPLC1:  254 nm, tR 5.42 min, purity 86%. 
5-(4-Amino-butyl)-1-(6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-3-(1-
hydroxy-ethylidene)-pyrrolidine-2,4-dione (5b).  To 0.81 g (0.182 mmol) of 4b were 
added 1 mL THF and 0.5 mL TFA.  The reaction was stirred at r. t. for approximately 1.5 
h, then evaporated.  The product was then reacted again with 1 mL THF and 0.5 mL TFA 
for 1 h, then evaporated to a dark brown gel.  1H NMR (500 MHz):  0.74-0.80 (1H, m), 
0.83 (3H, s), 0.97-1.06 (1H, m), 1.06-1.20 (1.93H, m), 1.21-1.31 (5H; mainly a single 
large peak), 1.31-1.38 (1.57H, m), 1.46 (3.67H, s), 1.60 (0.68H, s), 1.63-1.81 (4H, m), 
1.81-2.02 (6.09H, m), 2.02-2.07 (1.28H, m), 2.17 (1.74H, bs), 2.18-2.32 (2.92H, m), 
2.32-2.40 (1.64H, m), 2.41-2.49 (3.43H; two unequal peaks); 2.53 (0.54H, t, J = 8 Hz), 
2.95-3.12 (2.12H, m), 3.32 (0.87H, J = 13.2), 3.43 (0.46H, t, J = 15 Hz), 3.64-4.08 (5.41, 
m), 4.08-4.18 (0.44H, m), 4.33-4.46 (1.12H, m), 4.47-4.57 (0.92H, m), 5.41 (0.35H, s), 
5.49 (0.9H, s), 7.48 (1.88H, s).  ESI-MS:  (+) 347.2 (M + 1).  HPLC2:  254 nm, tR 1.68 
min, purity 88%. 
 
5-(4-Amino-butyl)-1-decyl-3-(1-hydroxy-ethylidene)-pyrrolidine-2,4-dione (5c).  To 
0.392 g (0.866 mmol) of 4c were added 3 mL THF and 2 mL TFA.  The reaction was 
stirred at r. t. for 1 h, then evaporated.  The solution was then reacted again with 3 mL 
THF and 2 mL TFA, then evaporated to a somewhat darker brownish oil.  Prior to 
antimicrobial testing, portions of this product were purified by use of a Gilson preparative 
HPLC reversed-phase column and combined.   1H NMR (500MHz, CDCl3):  0.92 (3H, t), 
1.08-1.18 (0.88H, m), 1.18-1.37 (15.41H, m dominated by large singlet), 1.39-1.53 
(5.75H, m including large singlet), 1.54-1.64 (1.56H, m), 1.66-1.81 (1.71H, m), 1.87-2.02 
(1.75H, m), 2.06 (0.81H, s), 2.19 (0.19H, s), 2.24-2.29 (0.36H, m), 2.29-2.34 (0.34H, m), 
2.34-2.36 (0.19H, m), 2.4 (2.32H, dd, J = 10 Hz), 2.98-3.12 (2.09H, m), 3.18-3.28 
(0.36H, m), 3.72-3.90 (2.34H, m), 4.12 (0.4H, q, J = 7.17 Hz), 4.23-4.42 (0.43H, m), 7.61 
(0.7H, bs).  ESI-MS:  475.3 (M+23). HPLC3:  254 nm, tR 4.52 min, purity 59%. 
 
5-(4-Amino-butyl)-1-(4-ethyl-benzyl)-3-(1-hydroxy-ethylidene)-pyrrolidine-2,4-
dione (5d).  To 0.078 g of 4d were added 1 mL THF and 0.5 mL TFA.  The reaction was 
allowed to proceed at r. t. for 11.5 h, then evaporated to form a brown sticky semisolid.  
1H NMR (500 MHz, CD3OD):  0.88-0.94 (0.87H, m), 1.01-1.09 (0.60Hz, m), 1.10-1.18 
(0.79H, m), 1.23 (3.60H, t, J = 7.5 Hz), 1.26-1.39 (4.14H, m), 1.44 (4H, s), 1.72-1.95 
(1.93H, m), 2.47 (2H, s), 2.65 (2H, q, J = 7.67 Hz), 2.78-2.84 (0.42H, m), 2.94 (0.67H, t, 
J = 6.25), 3.33 (2.32H, t, J = 1.5 Hz), 3.72-3.80 (0.66H, m), 4.25-4.31 (0.53H, d, J = 15 
Hz), 4.85-4.98 (17H, large singlet and small multiplet), 7.13-7.28 (3.43H, m). ESI-MS:  
(+) 331.2 (M + 1). HPLC1:  254 nm, tR 5.27 min, purity 41%. 
 
5-(4-Amino-butyl)-3-(1-hydroxy-ethylidene)-1-(4-methoxy-benzyl)-pyrrolidine-2,4-
dione (5e).  To 0.56 g (0.13 mmol) of 4e were added 2 mL THF and 0.5 mL TFA.  The 
reaction was stirred for 1.5 hours at r. t., then evaporated.  The product was then reacted a 
second time with 1 mL THF and 0.5 mL TFA for 1 h, then evaporated to form a brown 
sticky semisolid.  1H NMR (500 MHz, CD3OD):  0.92 (0.94H, t, J = 6.75 H), 1.08-1.26 
(2.42H, m), 1.26-1.38 (8.28H, m), 1.39-1.46 (3.09H, m, two main peaks), 1.48-1.63 
(1.87H, m), 1.73-1.94 (1.88H, m), 2.22 (0.36H, t, J = 8 Hz), 2.29 (0.38H, t, J = 7.5 Hz), 
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2.46 (2.38H, s), 2.61 (0.17H, s), 2.82 (1.2H, t, J = 6.75 Hz), 2.92-2.98 (0.46H, m), 3.23 
(2H, q, J = 7.67 Hz), 3.33 (1.24H, s), 3.37 (1.62H, s), 3.70-3.83 (4.18H, single peak amid 
multiplet), 4.19-4.30 (0.86H, mainly doublet at 4.26 and J = 15 Hz), 4.85-5.03 (8.7H, 
singlet merged with smaller peaks), 6.91 (2H, d, J = 7 Hz), 7.27 (2H, d, J = 7.5 Hz).  ESI-
MS:  (+) 333.2 (M + 1).  HPLC4:  254 nm, tR 6.34 min, purity 81%. 
 
 
Biology 
 
Microbiological Testing  
 
The minimum inhibitory concentrations (MICs) of the tetramic acids were determined by 
incubation in Mueller-Hinton media in 96-well microplates containing doubling dilutions 
of antibiotic, with bacterial concentration of approximately 105 colony-forming units per 
milliliter.  After overnight growth at 37°C, the MIC was recorded as the lowest 
concentration of antibiotic that impeded visible bacterial growth. 
 
 
Hemolysis Assay 
 
The hemolytic activity of tetramic acids against mammalian blood cells was tested 
against horse erythrocytes (BD Biosciences).  A stock suspension (10% vol/vol) was 
prepared in phosphate-buffered saline (pH 7.2).  Before analysis, the stock suspension 
was diluted to 1 in 20 with saline, and 360 µL aliquots were measured into sterile 
microcentrifuge tubes.  Following incubation for 15 min at 37°C, 40 µL of tetramic acid 
compounds were added to give final concentrations of 100, 10, or 1 µg/mL.  The 
antibiotics used as non-hemolytic negative controls, ampicillin and doxycycline, were 
tested at a concentration of 10 µg/mL, whereas the positive control, the detergent Triton-
X 100 (inducing 100% lysis), was tested at 0.1% vol/vol.  After an incubation period of 1 
h at 37°C, the reaction mixtures were centrifuged and 200 µL of supernatant transferred 
to 96 well flat-bottom microtiter plates.  The absorbance of hemoglobin released from 
cells was determined by OD540nm  readings on a Synergy HT Biotek plate reader.  Based 
on OD540nm readings, the % hemolysis was determined as 100 x (OD540 of sample - OD540 of 
sample blank) / (OD540 of Triton-X 100 - OD540 of Triton-X blank). 
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